ECM
IMVT icon

ExodusPoint Capital Management’s Immunovant IMVT Stock Holding History

ExodusPoint Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-107,300
Closed -$1.13M – 2361
2021
Q2 		$1.13M Buy
+107,300
New +$1.5M 0.01% 944

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ExodusPoint Capital Management's IMVT Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 21,941 shares — an estimated $545K sold.

ExodusPoint Capital Management first reported a position in IMVT in Q4 2019 and held it in 17 quarters. The position peaked at $3.87M in Q2 2025. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • ExodusPoint Capital Management reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 21,941 Immunovant shares in Q2 2026, an estimated $545K.
  • ExodusPoint Capital Management first reported a position in Immunovant in Q4 2019 and held it in 17 quarters.
  • ExodusPoint Capital Management's Immunovant position peaked at $3.87M in Q2 2025.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.